Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
25.87 CHF | -1.98% |
|
-2.92% | +2.82% |
28/06 | US urges dismissal of lawsuit seeking menthol cigarette ban | RE |
24/06 | European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Its low valuation, with P/E ratio at 7.77 and 7.25 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an enterprise value anticipated at 3.28 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Tobacco
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.82% | 68.62B | - | ||
+7.62% | 157B | B- | ||
+12.26% | 21.73B | A- | ||
+38.46% | 7.44B | B- | ||
+101.47% | 2.65B | - | C+ | |
-1.41% | 1.8B | - | ||
-3.01% | 1.72B | - | D+ | |
-29.23% | 1.17B | - | B+ | |
0.00% | 646M | - | - | |
+23.21% | 571M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BATS Stock
- BATS Stock
- Ratings British American Tobacco p.l.c.